ESR1 and breast cancer: Brechbuhl and colleagues identified that the contribution of CAF subpopulations to therapeutic resistance varies, with CD146+ CAFs in estrogen receptor (ER) positive breast cancer cells displaying sensitivity to tamoxifen treatment, while CD146- CAFs were correlated with decreased ER expression in the same cells and thus increased resistance to tamoxifen treatment (71).